Published in Blood on April 01, 1987
Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J (1992) 2.27
Polymerization of fibrin: specificity, strength, and stability of knob-hole interactions studied at the single-molecule level. Blood (2005) 1.45
Polymerization of fibrin: Direct observation and quantification of individual B:b knob-hole interactions. Blood (2006) 1.18
Cl- regulates the structure of the fibrin clot. Biophys J (1998) 1.13
Identification of covalently linked trimeric and tetrameric D domains in crosslinked fibrin. Proc Natl Acad Sci U S A (1989) 1.10
Three-dimensional reconstruction of fibrin clot networks from stereoscopic intermediate voltage electron microscope images and analysis of branching. Biophys J (1995) 1.04
The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (gamma 275 Arg-->Cys). J Clin Invest (1995) 0.97
Fibrin clots are equilibrium polymers that can be remodeled without proteolytic digestion. Sci Rep (2012) 0.96
Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense. Blood (2015) 0.91
Comparison of two gelatin and thrombin combination hemostats in a porcine liver abrasion model. J Invest Surg (2013) 0.86
Binding of alpha-thrombin to fibrin depends on the quality of the fibrin network. Biochem J (1994) 0.84
Fibrinogen Stony Brook, a heterozygous A alpha 16Arg----Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly. J Clin Invest (1989) 0.82
Structural effects of methionine oxidation on isolated subdomains of human fibrin D and αC regions. PLoS One (2014) 0.82
Abnormal fibrinogens IJmuiden (B beta Arg14----Cys) and Nijmegen (B beta Arg44----Cys) form disulfide-linked fibrinogen-albumin complexes. Proc Natl Acad Sci U S A (1992) 0.78
The relationship between the fibrinogen D domain self-association/cross-linking site (gammaXL) and the fibrinogen Dusart abnormality (Aalpha R554C-albumin): clues to thrombophilia in the "Dusart syndrome". J Clin Invest (1996) 0.76
Clots of beta-fibrin. Viscoelastic properties, temperature dependence of elasticity, and interaction with fibrinogen-binding tetrapeptides. Biophys J (1988) 0.75
The cold-insoluble globulin of human plasma. I. Purification, primary characterization, and relationship to fibrinogen and other cold-insoluble fraction components. J Biol Chem (1970) 4.49
Receptors for cold-insoluble globulin (plasma fibronectin) on human monocytes. J Exp Med (1981) 3.93
Interactions among heparin, cold-insoluble globulin, and fibrinogen in formation of the heparin-precipitable fraction of plasma. J Clin Invest (1977) 2.96
The structure and biologic activities of plasma fibronectin. Blood (1980) 2.94
Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol (2000) 2.58
The cold-insoluble globulin of human plasma: studies of its essential structural features. Biochim Biophys Acta (1975) 2.51
The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci (2001) 2.48
Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet (2001) 2.43
Identification and mass analysis of human fibrinogen molecules and their domains by scanning transmission electron microscopy. J Mol Biol (1981) 2.01
Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther (2005) 1.95
Antithrombotic therapy for venous thromboembolic disease. Chest (2001) 1.94
Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol (2001) 1.76
Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood (1980) 1.75
Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost (2009) 1.68
Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis (2001) 1.67
Antithrombotic therapy for venous thromboembolic disease. Chest (1998) 1.67
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ (1991) 1.65
Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol (2001) 1.59
SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res (2000) 1.55
Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes. J Clin Invest (1973) 1.54
Heterogeneity of the cold-insoluble globulin of human plasma (CIg), a circulating cell surface protein. Biochim Biophys Acta (1977) 1.54
Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Eur J Gastroenterol Hepatol (1995) 1.52
Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost (2001) 1.48
Diabetic control in 102 insulin-treated out-patients. Diabetologia (1980) 1.47
Problems of oral anticoagulation in an adult with homozygous protein C deficiency and late onset of thrombosis. Thromb Haemost (1993) 1.44
A European view on the North American fifth consensus on antithrombotic therapy. Chest (2000) 1.43
The role of fibroblasts in organization and degradation of a fibrin clot. J Lab Clin Med (1991) 1.42
Reversibility of thrombin-induced decrease in platelet glycoprotein Ib function. Br J Haematol (1993) 1.40
Cerebral infarction and familial protein S deficiency. Stroke (1990) 1.39
Fast MR imaging of the liver: quantitative comparison of techniques. Radiology (1994) 1.38
Detection and quantitation of fibronectin in synovial fluid from patients with rheumatic disease. Arthritis Rheum (1981) 1.38
Rapid aequorin loading into platelets in the presence of DMSO--characteristics of the responses (changes in light transmission and in calcium) to various agonists. Thromb Haemost (1991) 1.38
Human fibrinogen heterogeneities. I. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates. J Biol Chem (1972) 1.37
Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A (1998) 1.37
Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer (1996) 1.36
Electron microscopy of fine fibrin clots and fine and coarse fibrin films. Observations of fibers in cross-section and in deformed states. J Mol Biol (1984) 1.34
Production of fibronectin by human epithelial cells in culture. Cancer Res (1979) 1.34
The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry (1966) 1.31
Enzymatic resynthesis of the hydrolyzed peptide bond(s) in ribonuclease S. Biochemistry (1979) 1.28
Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost (1995) 1.28
The association of center performance evaluations and kidney transplant volume in the United States. Am J Transplant (2013) 1.28
Mechanical impact induces cartilage degradation via mitogen activated protein kinases. Osteoarthritis Cartilage (2010) 1.25
Fibronectin fragments in osteoarthritic synovial fluid. J Rheumatol (1992) 1.25
[Coagulation disorders after reinjection of concentrated ascitic fluid. Preliminary study]. Med Chir Dig (1973) 1.22
Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J Clin Invest (1979) 1.22
Control of a cell surface major glycoprotein by epidermal growth factor. Science (1977) 1.21
Human fibroblasts bind directly to fibrinogen at RGD sites through integrin alpha(v)beta3. Exp Cell Res (1997) 1.19
Small abnormal echos after mitral valve replacement with bileaflet mechanical prostheses: predisposing factors and effect on thromboembolism. J Heart Valve Dis (1993) 1.19
Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res (2001) 1.18
The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb Haemost (1996) 1.17
Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol (1997) 1.17
Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility. Biochemistry (1967) 1.17
Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry (1996) 1.16
An improved method for purification of the cold-insoluble globulin of human plasma (CLg). Anal Biochem (1977) 1.16
Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulant treatment. Thromb Haemost (1984) 1.16
Fibrinopeptide B and aggregation of fibrinogen. Science (1979) 1.15
Mural aortic thrombi: An important cause of peripheral embolization. J Vasc Surg (1999) 1.15
Cell surface fibrinogen-fibrin receptors on cultured human fibroblasts. Association with fibronectin (cold insoluble globulin, LETS protein) and loss in SV40 transformed cells. Lab Invest (1979) 1.15
Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Pathol (1985) 1.14
Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem (1996) 1.13
Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci (2003) 1.12
Synthesis of peptide bonds by proteinases. Addition of organic cosolvents shifts peptide bond equilibria toward synthesis. Biochemistry (1978) 1.12
[Value of the platelet count using electronic counter]. Pathol Biol (Paris) (1970) 1.11
Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther (1998) 1.10
Identification of covalently linked trimeric and tetrameric D domains in crosslinked fibrin. Proc Natl Acad Sci U S A (1989) 1.10
Studies on a procoagulant fraction of southern copperhead snake venom: the preferential release of fibrinopeptide B. J Lab Clin Med (1970) 1.10
Specific protein and glycoprotein deficiencies in platelets isolated from two patients with the gray platelet syndrome. Blood (1982) 1.10
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer (2003) 1.10
Cryoprecipitation of fibrin-fibrinogen complexes induced by the cold-insoluble globulin of plasma. Blood (1978) 1.10
Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med (1986) 1.10
Glycosylated haemoglobin concentrations and clinitest results in insulin-dependent diabetes. Lancet (1977) 1.09
Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol (2001) 1.08
Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (gamma'). Proc Natl Acad Sci U S A (1980) 1.08
Acceleration of fibrin polymerization by calcium ions. Blood (1972) 1.07
Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia (2009) 1.06
Cross-linking of fibrinogen and fibrin by fibrin-stablizing factor (factor XIIIa). J Lab Clin Med (1975) 1.06
Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci U S A (2000) 1.06